Literature DB >> 25064842

New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling.

Haiqi Lu1, Wei Jin1, Jie Sun2, Lifeng Feng2, Huiyin Lan2, Qi Shen1, Yanning Ma2, Jiaqiu Li1, Yongfang Yue2, Hongchuan Jin2, Xian Wang3.   

Abstract

As a well-characterized master player in epigenetic regulatory network, EZH2 is widely implicated in the development of many malignancies. We previously found that EZH2 promoted Wnt/β-catenin activation through downregulation of CXXC4 expression. In this report, we demonstrated that CXXC4 inhibited MAPK signaling through binding to ERK-1/2 and abrogating the interaction of ERK 1/2 with MEK1/2. L183, the critical residue in CXXC4 ERK D domain, was found to be essential for CXXC4-ERK 1/2 interaction and the growth inhibitory effect of CXXC4 in human cancer cells. In summary, CXXC4 directly disrupted MEK1/2-ERK 1/2 interaction to inactivate MAPK signaling. L183 site is indispensable for the binding of CXXC4 to ERK1/2 and growth inhibitory effect of CXXC4. Therefore, EZH2 can activate MAPK signaling by inhibiting CXXC4 expression.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CXXC finger protein 4 (CXXC4); Enhancer of zeste homologue 2 (EZH2); Extracellular signal-regulated kinase (ERK); Gastric carcinogenesis; MAP kinase (MEK); Mitogen-activated protein kinase (MAPK)

Mesh:

Substances:

Year:  2014        PMID: 25064842     DOI: 10.1016/j.febslet.2014.07.014

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

2.  The role of the WNT signaling pathway in the maxillary sinus squamous cell carcinoma.

Authors:  Bakiye Goker Bagca; Cigir Biray Avci; Baha Sezgin; Ali Veral; Sercan Gode; Halil Bulent Karci
Journal:  Med Oncol       Date:  2022-01-29       Impact factor: 3.064

3.  The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.

Authors:  Zeyou Wang; Qin Guo; Rong Wang; Gang Xu; Peiyao Li; Yingnan Sun; Xiaoling She; Qiang Liu; Qiong Chen; Zhibin Yu; Changhong Liu; Jing Xiong; Guiyuan Li; Minghua Wu
Journal:  J Hematol Oncol       Date:  2016-11-25       Impact factor: 17.388

4.  CXXC finger protein 4 inhibits the CDK18-ERK1/2 axis to suppress the immune escape of gastric cancer cells with involvement of ELK1/MIR100HG pathway.

Authors:  Ping Li; Dongfang Ge; Pengfei Li; Fangyong Hu; Junfeng Chu; Xiaojun Chen; Wenbo Song; Ali Wang; Guangyu Tian; Xiang Gu
Journal:  J Cell Mol Med       Date:  2020-07-26       Impact factor: 5.310

5.  CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.

Authors:  Mengjiao Han; Dongjun Dai; Neelum Aziz Yousafzai; Faliang Wang; Hanying Wang; Qiying Zhou; Haiqi Lu; Wenxia Xu; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Oncotarget       Date:  2017-10-06

6.  MiR-629-5p promotes colorectal cancer progression through targetting CXXC finger protein 4.

Authors:  Jinlai Lu; Shuirong Lu; Jingze Li; Qi Yu; Lang Liu; Qin Li
Journal:  Biosci Rep       Date:  2018-08-29       Impact factor: 3.840

7.  Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer.

Authors:  Margarita Kirienko; Martina Sollini; Marinella Corbetta; Emanuele Voulaz; Noemi Gozzi; Matteo Interlenghi; Francesca Gallivanone; Isabella Castiglioni; Rosanna Asselta; Stefano Duga; Giulia Soldà; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-07       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.